{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-027037","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.602203+00:00","generated_at":"2026-05-15T12:56:20.337407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Capricor FY2025 net loss $105M; Deramiocel PDUFA date Aug 22, 2026","bullets":["Net loss of $30.2M in Q4 2025 ($0.62/sh) and $105.0M for FY2025 ($2.26/sh).","Revenue was $0 in Q4 and FY2025, vs $11.1M and $22.3M in prior-year periods, as Nippon Shinyaku milestones fully recognized.","Cash, equivalents and marketable securities $318.1M at Dec 31, 2025, up from $151.5M; expected to fund operations through 2027.","BLA for Deramiocel in Duchenne muscular dystrophy under FDA review; PDUFA target date August 22, 2026.","Phase 3 HOPE-3 trial met primary endpoint (PUL v2.0, p=0.03) and key cardiac endpoint (LVEF, p=0.04)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-027037","json":"https://secwatch.observer/filing/0001104659-26-027037.json","markdown":"https://secwatch.observer/filing/0001104659-26-027037.md","text":"https://secwatch.observer/filing/0001104659-26-027037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/0001104659-26-027037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:56:20.337407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8268b50ec00b21f492bef4f48a045a95920e7cf0","claim":"CAPRICOR THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2025 results: revenue $0.","evidence_excerpt":"Revenues for the fourth quarter of 2025 were $0","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/0001104659-26-027037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$0"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}